LCTX Lineage Cell Therapeutics, Inc. Insider Trading

LCTX CEO Culley buys 15,000 shares at $1.62; stock down 19.4% from 52-week high, trading -14.1% over 30 days

Brian M. Culley, President and CEO, purchased 15,000 shares at $1.62 on 2026-03-12, increasing his holdings by 6.2% to 255,516 shares total. The transaction occurs amid deteriorating near-term price action: LCTX has fallen 14.1% over the past 30 days and 19.4% from its 52-week high of $1.96, creating a meaningful gap between the transaction price and current trading levels. Culley's prior two purchases at LCTX show mixed outcomes — one delivered a 90-day gain of 19.8%, while the other posted a 90-day loss of 15.0% — providing limited directional clarity about insider timing acumen at this specific stock. The company's fundamentals remain challenged: it reported a quarterly revenue of $3.7M alongside a net loss of $29.8M, though annual revenue is growing 53.2%, indicating significant operational losses persist despite top-line expansion and a $393.6M market cap.

Director Broadwood Partners buys 7,894,737 shares at $0.76 for $6M, raising stake 18.9% amid -39.2% annual revenue decline

Broadwood Partners, a director of Lineage Cell Therapeutics, executed 2 separate purchases totaling 7,894,737 shares for $6,000,000.12 at $0.76 per share on 2025-01-27, increasing total holdings from 41,666,255 to 49,560,992 shares (+18.9%). The transaction occurs at a price ($0.76) significantly above the current market price of $0.63 and within the 52-week range ($0.50–$1.48). However, the company's fundamentals present material headwinds: annual revenue growth contracted -39.2%, the latest quarterly revenue was only $3,779,000.00, and the company generated a net loss of $-3,034,000.00 in the most recent quarter, with negative full-year net income. Broadwood's cross-ticker track record shows a 50.00% win rate and average 90-day returns of -2.9%, though its prior 2 trades at LCTX (both on 2024-02-06) were well-timed at the 90-day horizon with +25.0% and +17.1% returns respectively. The scale of this purchase—an 18.9% increase in holdings deployed at a price now 20.6% above the current market level—paired with steep revenue decline and ongoing losses, warrants investor attention to the company's cash position and the director's conviction thesis.

CFO Jill Ann Howe buys 15,000 LCTX shares at $0.59; stock down -59.5% from 52-week high, company unprofitable.

CFO Jill Ann Howe purchased 15,000 shares at $0.59 on 2024-11-26, increasing her holdings by 142.9% to 25,500 shares total. This buy occurs amid significant price weakness: the stock trades at $0.60, down -59.5% from its 52-week high and -28.7% over the prior 30 days. The company reported negative net income of $-3,034,000.00 in the latest quarter and is unprofitable on a full-year basis, with annual revenue declining -39.2% year-over-year. Notably, a cluster of 3 other insiders also purchased within the past 14 days, and Howe's prior open-market buy at this same ticker (2024-08-16) showed a -0.6% 90-day return—a pattern of poor timing on her past trades. The combination of accelerating losses, revenue contraction, depressed valuation, and an insider track record showing 0% win rate on 90-day holds raises material questions about the sustainability of the current operations.

General Counsel Samuel George A. III purchases 15,000 shares at $0.60 as part of cluster buy; stock down 59.5% from 52-week high amid -39.2% annual revenue decline.

Samuel George A. III, as General Counsel, purchased 15,000 shares at $0.60, increasing his holdings by 208.8% to 22,184 shares. This purchase is part of a cluster buy pattern with 3 other insiders also buying within the past 14 days. The transaction occurs against a backdrop of significant operational deterioration: annual revenue declined 39.2%, the company generated a net loss of $3,034,000.00 in its latest quarter, and the stock has fallen 59.5% from its 52-week high of $1.48. The substantial insider accumulation at these depressed levels, combined with concurrent buying by multiple executives, occurs as the company faces profitability challenges and sharply declining revenue, warranting scrutiny of whether insiders possess non-public information regarding a strategic inflection.

Director Mulroy bought 40.0K LCTX shares at $0.57 amid -61.5% 52-week decline; company posting losses

Michael H. Mulroy, a Director, purchased 40,000 shares at $0.57 on 2024-11-22, increasing his holdings by 15.5% to 298,555 shares. The purchase occurs in a context of material stock price deterioration: the current price of $0.57 sits -61.5% below the 52-week high of $1.48 and the stock has declined -32.2% over the past 30 days and -37.2% over 90 days. Fundamentally, Lineage Cell Therapeutics faces headwinds including annual revenue contraction of -39.2%, a net loss of $-3,034,000 in the latest quarter on revenue of $3,779,000, and negative full-year net income. The Director's accumulation at a depressed price level amid operational losses presents a factual record of insider acquisition activity that warrants examination of whether this represents conviction in recovery prospects or reflects other dynamics.

CEO Brian M Culley bought 40,000 shares of LCTX at $0.60 on 2024-11-21; stock down 42.6% in 30 days, trading at $0.50.

Brian M Culley, President and CEO, purchased 40,000 shares at $0.60, increasing his holdings by 25.8% to 194,842 shares. The acquisition occurs amid material deterioration: the stock has declined 42.6% over the past 30 days and 47.3% over 90 days, trading 66.2% below its 52-week high of $1.48. The company faces structural headwinds—annual revenue contracted 39.2% year-over-year to $3.8M in the latest quarter, the company is unprofitable (most recent full-year net income was negative), and the current market cap of $94.4M reflects significant investor skepticism. Culley's prior buy at this ticker on 2024-05-24 posted a 90-day return of -15.0%, establishing a pattern of purchases into declining positions without subsequent recovery. This transaction warrants scrutiny given the combination of deteriorating fundamentals, sustained price weakness, and the insider's historical inability to time entries ahead of further declines.

CFO Jill Ann Howe purchases 10,500 shares of LCTX at $0.89 amid -39.2% annual revenue decline and $-5.8M net loss.

CFO Jill Ann Howe purchased 10,500 shares (10.5K shares) at $0.89 on 2024-08-16, establishing an initial position in Lineage Cell Therapeutics. This purchase occurred in a deteriorating financial environment: the company reported annual revenue growth of -39.2%, generated a net loss of $-5.8M on quarterly revenue of $1.4M, and the stock has declined -40.5% from its 52-week high of $1.48. At $0.88 current price, the transaction is underwater by approximately -1% relative to the purchase price. The buy coincides with significant operational challenges and negative momentum, warranting closer examination of whether this reflects management's assessment of valuation or other strategic considerations.